« Return to News | Technology Solutions

Genstar Capital to acquire ERT

Tuesday, April 10, 2012 11:24 AM

Philadelphia-based eResearch Technology, a technology-driven provider of health outcomes research services to sponsors and CROs, has agreed to be acquired by affiliates of Genstar Capital, a middle market private equity firm, for $8 per share in cash in a transaction valued at approximately $400 million.

The proposed transaction has been approved unanimously by the ERT board of directors. The $8 per share represents a premium of approximately 38% over ERT's average closing share price for the 90 trading days ending April 9, 2012, and 42% over the 52-week average.

"We are pleased to announce this transaction with Genstar, whose experienced team of healthcare executives can provide strategic oversight, as well as acquisition capital,  to expand the company's service offering and market opportunities,” said Dr. Jeffrey Litwin, CEO of ERT. “They will help position ERT to better serve our clinical research clients by continuing to fund the innovative devices and services that have made us the premier provider of health outcomes research services."

Robert Weltman, managing director of Genstar, said, "ERT is an attractive opportunity that fits with Genstar's outsourcing thesis within the life sciences and pharmaceutical services sector. We are excited about helping the company evolve its offering and better serve its customers."

Pending stockholder approval and satisfaction of normal regulatory and closing conditions, the transaction is expected to be completed during the third quarter, after which ERT will become a privately held company and its stock will no longer trade on Nasdaq.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.